[Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].

Autor:	Fonseca FA; Escola Paulista de Medicina-UNIFESP, Sö Paulo., Novazzi JP, Cendoroglo MS, Duarte M, Almeida Pinto LE, Rabelo LM, da Rocha Martinez TL
Jazyk:	portugalština
Zdroj:	Arquivos brasileiros de cardiologia [Arq Bras Cardiol] 1996 Jan; Vol. 66 (1), pp. 33-5.
Abstrakt:	Purpose: To evaluate modifications on lipid profile, fibrinogen and platelet aggregation induced by etofibrate. Methods: Twenty-one adult patients were studied. They all had primary hyperlipidemia and had already been on the AHA step I diet and placebo. Etofibrate (500mg/day) was administered for 60 days in the active phase, when lipid parameters, fibrinogen and platelet aggregation were measured. Results: The % significant reductions were: total cholesterol (-9.50%), LDL-cholesterol (-7.88%), triglycerides (-19.07%), total cholesterol/HDL-cholesterol(-11.90%), LDL-cholesterol/HDL-cholesterol (-10.20%), fibrinogen (-12.79%), platelet aggregation with adrenaline (-24.02%), with ADP 1 mumol (-30.13%), and ADP 3 mumol (-24.51%). Conclusion: The beneficial effects of etofibrate were observed not only on the lipid profile but also on the thrombogenic parameters measured by fibrinogen and platelet aggregation.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu